Antag Therapeutics

Antag Therapeutics is a Danish clinical-stage biotechnology company developing a new class of therapies for obesity, type 2 diabetes and overweight. Founded in 2017 and headquartered in Copenhagen, the company is pioneering GIP receptor antagonism — an approach that blocks a dysfunctional biological pathway contributing to fat storage, insulin resistance and metabolic dysfunction, rather than stimulating incretin hormones to suppress appetite. Its lead candidate, AT-7687, is described as the first clinical-stage GIP receptor antagonist peptide and is being investigated both as a monotherapy and in combination with other obesity therapies. Antag positions itself around tolerability and long-term sustained health, aiming to address drawbacks of existing treatments such as gastrointestinal side effects and loss of lean mass. The company is privately held and has raised significant venture financing, including a reported €80 million Series A. Its leadership combines deep pharmaceutical R&D experience, with CEO Philip Just Larsen (appointed 2026) having previously led research at Bayer, Novo Nordisk, Eli Lilly, AstraZeneca and Sanofi, and co-founder Alexander H. Sparre-Ulrich serving as COO after founding the company and serving as its first CEO.

Antag Therapeutics was founded in 2017 in Copenhagen, Denmark, with Alexander H. Sparre-Ulrich serving as founding CEO from 2017 to 2024. The company was established to pursue a differentiated approach to obesity treatment based on GIP receptor antagonism, a mechanism distinct from the incretin-stimulating therapies that dominate the obesity market. Under Sparre-Ulrich's leadership, Antag advanced from drug candidate optimization through IND acceptance and secured a reported €80 million Series A financing. In 2026, Philip Just Larsen, who had chaired Antag's Board of Directors from January 2018 until March 2026, was appointed CEO. Larsen brought more than 20 years of pharmaceutical R&D leadership, including roles at Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi and Bayer, and as CEO of Sixpeaks Bio AG. At Eli Lilly, as CSO for Diabetes and Obesity, he led the initiation of the dual incretin agonist programmes that resulted in tirzepatide and mazdutide. Antag's lead candidate, AT-7687, is described as the first clinical-stage GIP receptor antagonist peptide and is being investigated as a monotherapy and in combination with other obesity therapies.

• 2026

  Philip Just Larsen appointed CEO (March 2026); previously board chair.

• 2024

  Alexander H. Sparre-Ulrich transitions from CEO to Co-founder & COO.

• 2018

  Philip Just Larsen begins chairing Antag's Board of Directors (January 2018).

• 2017

  Antag Therapeutics founded in Copenhagen; Alexander H. Sparre-Ulrich becomes founding CEO.

Differentiated obesity treatment via GIP receptor antagonism, emphasizing tolerability and long-term health beyond weight loss.

• AT-7687

  First clinical-stage GIP receptor antagonist peptide, investigated as monotherapy and in combination with other obesity therapies.

• 2021-07-15

  Antag Therapeutics appoints Christine Fischette to its board[4]Antag Therapeutics任命Christine Fischette为董事prnewswire.co.uk

  Reported: 2021-07-15

  Antag Therapeutics announced the appointment of Dr. Christine Fischette to its Board of Directors.

1. 1Antag Therapeutics official websiteantagtx.com
2. 2Leadership team - Antag Therapeuticsantagtx.com
3. 3Wikidata entry for Antag Therapeuticswikidata.org
4. 4Antag Therapeutics任命Christine Fischette为董事prnewswire.co.uk